Bayer: Neoplasm Metastasis trials
The registry lists 22 Neoplasm Metastasis studies with Bayer as lead sponsor. 1 are open to participants now and 5 have results posted.
Phase 1 7Phase 2 8Phase 3 2Phase 4 2No phase 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate CancerRecruitingNCT06661122
- Radium-223 Dichloride Long-term Follow-up ProgramCompletedNCT02312960Phase 4Results posted
- Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)CompletedNCT01976741Phase 1Results posted
- A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)CompletedNCT01106352Phase 1/2Results posted
- Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) SubjectsCompletedNCT00865709Phase 2Results posted
- A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal MetastasesCompletedNCT00699751Phase 3Results posted
- A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone LevelsTerminatedNCT05301062
- Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid TumorsCompletedNCT03517956Phase 1
- A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat CancerCompletedNCT03215511Phase 1
- Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene FusionNo longer availableNCT03206931
- Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) SubjectsCompletedNCT02363855Phase 1
- Stivarga Regulatory Post-Marketing Surveillance Study in KoreaCompletedNCT02106858
- Dose Escalation Study of Radium-223 Dichloride in Patients With Advanced Skeletal MetastasesCompletedNCT01798108Phase 1
- Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard TherapyCompletedNCT01584830Phase 3
- Health Economic Evaluation of Primovist-enhanced Liver MRICompletedNCT00764621Phase 4
- Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the SkeletonCompletedNCT00748046Phase 1
- BAY88-8223, Does Response Study in HRPC PatientsCompletedNCT00667199Phase 2
- Extension Program for Bay 43-9006CompletedNCT00657254Phase 2
- A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate CancerCompletedNCT00459654Phase 2
- BAY88-8223, Dose Finding Study in Patients With HRPCCompletedNCT00337155Phase 2
- Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast CancerCompletedNCT00288249Phase 2
- Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer PatientsCompletedNCT00044525Phase 2